6-Mar-2026
Market Chameleon (Tue, 3-Mar 2:42 AM ET)
PRNewswire (Mon, 2-Mar 5:31 PM ET)
Relay Therapeutics Sets Stage for Major Clinical Milestones in 2026 on Solid Financial Ground
Market Chameleon (Fri, 27-Feb 3:59 AM ET)
Globe Newswire (Thu, 26-Feb 4:05 PM ET)
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
Globe Newswire (Mon, 23-Feb 4:05 PM ET)
Relay Therapeutics Sets Financial Results Date as Phase 3 Trials on Zovegalisib Progress
Market Chameleon (Fri, 20-Feb 3:40 AM ET)
Globe Newswire (Thu, 19-Feb 5:55 PM ET)
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Globe Newswire (Wed, 4-Feb 4:05 PM ET)
Globe Newswire (Tue, 3-Feb 7:00 AM ET)
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
Globe Newswire (Tue, 16-Dec 12:18 PM ET)
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Relay Therapeutics trades on the NASDAQ stock market under the symbol RLAY.
As of March 6, 2026, RLAY stock price climbed to $9.89 with 1,252,422 million shares trading.
RLAY has a beta of 2.04, meaning it tends to be more sensitive to market movements. RLAY has a correlation of 0.24 to the broad based SPY ETF.
RLAY has a market cap of $1.71 billion. This is considered a Small Cap stock.
Last quarter Relay Therapeutics reported $7 million in Revenue and -$.32 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.07.
In the last 3 years, RLAY traded as high as $19.23 and as low as $1.78.
The top ETF exchange traded funds that RLAY belongs to (by Net Assets): VTI, IWM, XBI, IWN, VXF.
RLAY has outperformed the market in the last year with a price return of +184.2% while the SPY ETF gained +18.7%. RLAY has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +28.8% and +13.7%, respectively, while the SPY returned -1.7% and -2.5%, respectively.
RLAY support price is $9.16 and resistance is $10.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RLAY shares will trade within this expected range on the day.
